Biotech catalysts, February 2027

46 tracked events across 36 companies

Clinical trial milestones, FDA decision dates, SEC filings and earnings scheduled for February 2027, compiled from ClinicalTrials.gov and SEC EDGAR.

DateTickerEventTypePhase
February 2, 2027 BIIB A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants Trial Milestone Phase 1
February 2, 2027 NUVB Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib Trial Milestone Phase 1
February 4, 2027 AZN A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 Trial Milestone Phase 1
February 4, 2027 NVS Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) Trial Milestone Phase 2
February 7, 2027 INSM A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment Trial Milestone Phase 1
February 8, 2027 ONC A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment Trial Milestone Phase 1
February 9, 2027 MRK A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012) Trial Milestone Phase 1
February 9, 2027 REGN Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation Trial Milestone Phase 2
February 10, 2027 AZN A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors Trial Milestone Phase 2
February 12, 2027 MRK Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) Trial Milestone Phase 2
February 12, 2027 OCGN A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa Trial Milestone Phase 3
February 15, 2027 LLY A Study of Mirikizumab Solution (LY3074828) in Healthy Participants Trial Milestone Phase 1
February 15, 2027 ABBV IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia Trial Milestone Phase 1/Phase 2
February 15, 2027 ABBV First in Human Study of IMGN151 in Recurrent Gynaecological Cancers Trial Milestone Phase 1
February 15, 2027 ABBV A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab Trial Milestone Phase 2
February 15, 2027 ABBV A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression Trial Milestone Phase 2
February 15, 2027 GILD Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) Trial Milestone Phase 1
February 15, 2027 ARGX A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis Trial Milestone Phase 2
February 15, 2027 SVA A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG) Trial Milestone Phase 4
February 15, 2027 NBIX Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia Trial Milestone Phase 2
February 15, 2027 MRNA A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis Trial Milestone Phase 3
February 15, 2027 ARWR A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus Trial Milestone Phase 1/Phase 2
February 15, 2027 KOD A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE Trial Milestone Phase 3
February 15, 2027 LQDA A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks Trial Milestone Phase 2
February 15, 2027 CADL A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec Trial Milestone Phase 2
February 15, 2027 DNLI A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease Trial Milestone Phase 1
February 15, 2027 KRYS A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs Trial Milestone Phase 1/Phase 2
February 15, 2027 SNDX A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias Trial Milestone Phase 1
February 15, 2027 GERN A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis Trial Milestone Phase 1
February 15, 2027 AMLX AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis Trial Milestone Phase 1
February 15, 2027 GNLX Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer Trial Milestone Phase 2
February 15, 2027 IRON A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) Trial Milestone Phase 2
February 15, 2027 XNCR Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma Trial Milestone Phase 1
February 15, 2027 SXTP B-FREE Chronic Babesiosis Study Trial Milestone Phase 2
February 17, 2027 SNY An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps Trial Milestone Phase 3
February 20, 2027 REGN REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults Trial Milestone Phase 3
February 22, 2027 NVS A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines Trial Milestone Phase 3
February 22, 2027 REGN Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity Trial Milestone Phase 1
February 23, 2027 PFE A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function Trial Milestone Phase 1
February 26, 2027 NVS Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation Trial Milestone Phase 3
February 26, 2027 NVS Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer Trial Milestone Phase 2
February 26, 2027 ARDX A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults Trial Milestone Phase 3
February 27, 2027 JAZZ A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants Trial Milestone Phase 1
February 28, 2027 INBS A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants Trial Milestone Phase 1
February 28, 2027 SGP Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension Trial Milestone Phase 1
February 28, 2027 NTHI Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Trial Milestone Phase 1/Phase 2

Build your own view. Pick the companies you follow and see only their catalysts.

Open the tracker

Companies on this page

BIIB · NUVB · AZN · NVS · INSM · ONC · MRK · REGN · OCGN · LLY · ABBV · GILD · ARGX · SVA · NBIX · MRNA · ARWR · KOD · LQDA · CADL · DNLI · KRYS · SNDX · GERN · AMLX · GNLX · IRON · XNCR · SXTP · SNY · PFE · ARDX · JAZZ · INBS · SGP · NTHI